The Cost Of Coronavirus: Medtech Market Wins And Losses

With the rapid global spread of the coronavirus, Medtech Insight looks at the predicted economic impact of the outbreak on the industry’s biggest businesses.

China Shanghai stock market crisis red price arrow down chart fall. The concept dependence of economic decline on spread disease. Business analytic infographics. Coronavirus 2019-nCov. Pandemic virus

Investor fears are at an all-time high over the impact of coronavirus as more than 80,000 people are reported to have been infected.

Cases of the coronavirus were first detected in Wuhan, the capital city of Hubei province in central China, and reported...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Diagnostics

More from Device Area

  • Owkin Teams With AstraZeneca To Develop AI-Based Breast Cancer Prescreening Tool

     

    Biopharmaceutical giant AstraZeneca has partnered with start-up “unicorn” Owkin to develop an AI-powered tool to prescreen for gBRCA mutations on the basis of morphological features in digitized pathology slides. Built on extensive, high-quality data sourced from the France-based PortrAIt consortium, the AI will help to prioritize patients for further testing, streamlining the diagnostic process, Owkin says.

  • Route 92 To Drive FreeClimb Neurointervention Sales With Extended Series F Funding

     

    An additional $50m brings the neurovascular intervention specialist’s total Series F funding to $82m. Route 92 says it will use the capital to build its sales and support teams and pursue regulatory authorizations around the globe for its FreeClimb portfolio while advancing its SUMMIT MAX clinical trial for the investigational Monopoint Reperfusion System.

  • TRiCares Initiates EU Pivotal Study For Topaz Tricuspid Valve Replacement

     

    TRiCares announced first implantation of the Topaz transfemoral tricuspid heart valve replacement system as part of the company’s EU pivotal study. If all goes to plan, the device will compete with Edwards’ Evoque system. The announcement follows the company’s $50m series D funding raise in July.